01 / DESIGN
What was studied?
The trials enrolled adults with moderate-to-severe obstructive sleep apnea and obesity. One studied participants without positive airway pressure at baseline; the other included participants receiving it.
02 / FINDINGS
What did the researchers report?
At 52 weeks, tirzepatide groups had larger reductions in the apnea-hypopnea index than placebo groups, alongside changes in weight and other measures. Gastrointestinal adverse events were common.
03 / LIMITS
How should it be interpreted?
These selected populations and monitored conditions matter. The findings are not instructions to stop an existing sleep-apnea treatment and do not establish effects in people without obesity.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.